EyePoint, Inc.

This article needs more citations. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "EyePoint, Inc." – news · newspapers · books · scholar · JSTOR (March 2020) (Learn how and when to remove this message)

The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. Please help demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "EyePoint, Inc." – news · newspapers · books · scholar · JSTOR (November 2024) (Learn how and when to remove this message)

EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).^{[citation needed]} QinetiQ continues to be a strategic partner.

In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.

See also

• Alimera Sciences, pSvida's partner on Iluvien

References

External links

• Official website
• "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
• pSivida Mesoporous silicon patent

This United States manufacturing company–related article is a stub. You can help Wikipedia by adding missing information.

• v
• t
• e

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by adding missing information.

• v
• t
• e